Document is current

Article History

Received: 10 February 2025

Accepted: 9 May 2025

First Online: 2 June 2025

Declarations

:

: Ethical approval was not required for this study as it is a review of existing literature and does not involve human subjects or patient data.

: Not applicable, as this study does not involve participants or data thereof.

: Not applicable, as this study does not include any individual data or identifying information.

: R. Lanzenberger received investigator-initiated research funding from Siemens Healthcare regarding clinical research using PET/MR and travel grants and/or conference speaker honoraria from Janssen-Cilag Pharma GmbH in 2023, and Bruker BioSpin, Shire, AstraZeneca, Lundbeck A/S, Dr. Willmar Schwabe GmbH, Orphan Pharmaceuticals AG, Janssen-Cilag Pharma GmbH, Heel and Roche Austria GmbH., and Janssen-Cilag Pharma GmbH in the years before 2020. He is a shareholder of the start-up company BM Health GmbH, Austria since 2019. M. Hacker received consulting fees and/or honoraria from Bayer Healthcare BMS, Eli Lilly, EZAG, GE Healthcare, Ipsen, ITM, Janssen, Roche, and Siemens Healthineers. L. Cocchi is involved in a not-for-profit clinic administering fMRI-guided brain stimulation therapy (Queensland Neurostimulation Centre). The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

: Not applicable.